Primary neuroendocrine neoplasms of the vulva: A review of the MITO rare cancer group.

Gynecologic oncology Gynecologic surgery Neuroendocrine neoplasms Neuroendocrine vulvar carcinoma Vulvar tumors

Journal

Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049

Informations de publication

Date de publication:
17 Nov 2023
Historique:
received: 26 04 2023
revised: 04 11 2023
accepted: 13 11 2023
pubmed: 18 11 2023
medline: 18 11 2023
entrez: 17 11 2023
Statut: aheadofprint

Résumé

Gynecological neuroendocrine neoplasms are rare entities and can be divided into two groups: carcinoids and neuroendocrine carcinomas. Due to their rarity their management is not standardized. The aim of this work is to summarize and discuss the current literature evidence on this pathology. A scoping literature review was performed in multiple databases. Thirty-one studies were included: 30 case reports and one case series. Patients' age ranged between 28 and 92 years. Surgery was the most used treatment and the surgical approach included local excision (N = 16/31; 51.6%) with (N = 5/16; 31.25%) or without (N = 11/16; 68.75%) inguinal lymphadenectomy. Adjuvant radiotherapy was delivered in 12 (38.7%) cases; instead, platinum-based therapies were frequently used when chemotherapy was chosen for adjuvant treatment. The overall survival ranged between 20 days to 4 years. However, further research is needed; currently, multimodal approach including surgery, chemotherapy and radiotherapy appeared safe and feasible for the treatment of these rare and aggressive diseases.

Identifiants

pubmed: 37977312
pii: S1040-8428(23)00289-5
doi: 10.1016/j.critrevonc.2023.104201
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

104201

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Amelia Barcellini (A)

Radiation Oncology Unit, Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy; Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy.

Tullio Golia D'Augè (T)

Department of Gynecological, Obstetrical and Urological Sciences, "Sapienza" University of Rome, Italy. Electronic address: tullio.goliadauge@uniroma1.it.

Vincenzo Dario Mandato (VD)

Unit of Obstetrics and Gynaecology, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.

Ilaria Cuccu (I)

Department of Gynecological, Obstetrical and Urological Sciences, "Sapienza" University of Rome, Italy.

Angela Musella (A)

Department of Gynecological, Obstetrical and Urological Sciences, "Sapienza" University of Rome, Italy.

Robert Fruscio (R)

University of Milan Bicocca, IRCCS San Gerardo, Monza, Italy.

Maria Giuseppa Vitale (MG)

Department of Oncology and Hematology, University Hospital of Modena, 41100 Modena, Italy.

Ruby Martinello (R)

Department of Medical Sciences, Institute of Obstetrics and Gynecology, University of Ferrara, Italy.

Giorgia Mangili (G)

Obstet-Gynecol Dept, San Raffaele Scientific Institute, IRCCS Milan, Italy.

Sandro Pignata (S)

Uro-Gynecological Medical Oncology, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G Pascale, Naples, Italy.

Innocenza Palaia (I)

Department of Gynecological, Obstetrical and Urological Sciences, "Sapienza" University of Rome, Italy.

Classifications MeSH